Outfitter Advisors LTD. Raises Stake in NxStage Medical, Inc. (NXTM)
Outfitter Advisors LTD. raised its position in NxStage Medical, Inc. (NASDAQ:NXTM) by 40.8% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 77,920 shares of the medical device company’s stock after buying an additional 22,570 shares during the period. Outfitter Advisors LTD.’s holdings in NxStage Medical were worth $1,953,000 at the end of the most recent reporting period.
A number of other institutional investors have also added to or reduced their stakes in the company. SG Americas Securities LLC acquired a new position in NxStage Medical during the first quarter worth approximately $140,000. Ameritas Investment Partners Inc. bought a new stake in NxStage Medical during the first quarter worth about $148,000. Menta Capital LLC bought a new stake in NxStage Medical during the first quarter worth about $212,000. Jane Street Group LLC bought a new stake in NxStage Medical during the first quarter worth about $213,000. Finally, PEAK6 Investments L.P. bought a new stake in NxStage Medical during the first quarter worth about $214,000. 91.11% of the stock is owned by hedge funds and other institutional investors.
NxStage Medical, Inc. (NASDAQ:NXTM) opened at 29.22 on Friday. The company’s 50-day moving average price is $24.92 and its 200-day moving average price is $25.85. The firm’s market capitalization is $1.93 billion. NxStage Medical, Inc. has a 12-month low of $20.45 and a 12-month high of $30.80.
NxStage Medical (NASDAQ:NXTM) last issued its quarterly earnings results on Monday, August 7th. The medical device company reported ($0.03) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.03). NxStage Medical had a negative return on equity of 2.43% and a negative net margin of 1.33%. The business had revenue of $92.20 million for the quarter, compared to analyst estimates of $96.47 million. During the same quarter in the prior year, the firm posted ($0.03) earnings per share. The firm’s revenue for the quarter was up .0% compared to the same quarter last year. Equities analysts expect that NxStage Medical, Inc. will post ($0.04) EPS for the current fiscal year.
TRADEMARK VIOLATION WARNING: This report was published by Daily Political and is the property of of Daily Political. If you are accessing this report on another publication, it was stolen and republished in violation of international copyright & trademark laws. The original version of this report can be viewed at https://www.dailypolitical.com/2017/08/13/outfitter-advisors-ltd-raises-stake-in-nxstage-medical-inc-nxtm.html.
A number of equities research analysts have issued reports on NXTM shares. Craig Hallum cut NxStage Medical from a “buy” rating to a “hold” rating in a research note on Monday, August 7th. BTIG Research reiterated a “buy” rating and issued a $27.00 target price on shares of NxStage Medical in a research note on Wednesday, May 10th. Jefferies Group LLC cut their target price on NxStage Medical from $38.00 to $33.00 and set a “buy” rating on the stock in a research note on Wednesday, May 10th. Canaccord Genuity reiterated a “buy” rating and issued a $32.00 target price on shares of NxStage Medical in a research note on Monday, May 8th. Finally, Stephens cut NxStage Medical from an “overweight” rating to an “equal weight” rating and cut their target price for the company from $33.00 to $30.00 in a research note on Wednesday. One analyst has rated the stock with a sell rating and eight have assigned a hold rating to the company’s stock. NxStage Medical presently has a consensus rating of “Hold” and a consensus target price of $30.29.
In other news, SVP Winifred L. Swan sold 3,500 shares of the company’s stock in a transaction on Monday, May 15th. The stock was sold at an average price of $21.94, for a total transaction of $76,790.00. Following the transaction, the senior vice president now owns 17,770 shares of the company’s stock, valued at $389,873.80. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, President Joseph E. Turk, Jr. sold 1,000 shares of the company’s stock in a transaction on Wednesday, July 5th. The shares were sold at an average price of $25.19, for a total value of $25,190.00. Following the transaction, the president now directly owns 75,903 shares in the company, valued at approximately $1,911,996.57. The disclosure for this sale can be found here. Insiders have sold 53,900 shares of company stock worth $1,404,073 in the last ninety days. 4.70% of the stock is currently owned by insiders.
About NxStage Medical
NxStage Medical, Inc is a medical technology company. The Company develops, manufactures and markets products and services for patients suffering from chronic or acute kidney failure. It operates through three segments. The System One segment includes revenues from the sale and rental of the System One and PureFlow SL dialysate preparation equipment and the sale of disposable products in the home and critical care markets.
Want to see what other hedge funds are holding NXTM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for NxStage Medical, Inc. (NASDAQ:NXTM).
Receive News & Ratings for NxStage Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NxStage Medical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.